Skip to main content

Advertisement

SpringerLink
Log in

Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Tumor biopsies are critical for delineating pharmacodynamic effects of drugs and for optimal patient selection during oncology clinical trials of molecular targeted therapies. The purpose of this study was to identify factors related to patients’ willingness to provide study-related tumor biopsies in phase 1 clinical trials of molecularly targeted therapy.

Methods

An investigator-designed survey, that assessed biopsy willingness, demographic and clinical factors, was completed anonymously by patients with advanced cancer in a phase 1 clinic for targeted therapy. Data were analyzed using multivariate logistic regression models with odds ratios (OR) and 95 % confidence intervals (CI).

Results

Three hundred and sixty-two patients with advanced cancer (50 % male, 56 % aged ≤60 years) participated. In univariate analyses, willingness to provide study-related biopsy was associated with male gender, white race, higher income, using the Internet for cancer-related information, and having had a biopsy previously (p < 0.05). In multivariate analyses, male gender (OR 2.41, 95 % CI 1.54, 3.78) and having had a biopsy (OR 3.71, 95 % CI 1.68, 8.15) were associated with willingness to have one biopsy; male gender (OR 1.97, 95 % CI 1.30, 3.00) and relying on the Internet as a source of information (OR 1.87, 95 % CI 1.21, 2.89) were associated with willingness to have more than one biopsy.

Conclusions

The results suggest that male gender is associated with greater stated willingness to undergo biopsy. Also, the Internet is an important source of information for patients with cancer and may strongly influence their decisions about whether to consent to biopsies in early clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Agulnik M, Oza AM, Pond GR, Siu LL (2006) Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. J Clin Oncol 24(30):4801–4807. doi:10.1200/jco.2005.03.4496

    Article  PubMed  Google Scholar 

  • Bernhard J, Dietrich D, Glimelius B, Hess V, Bodoky G, Scheithauer W, Herrmann R (2010) Estimating prognosis and palliation based on tumour marker CA 19–9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy. Br J Cancer 103(9):1318–1324. doi:10.1038/sj.bjc.6605929

    Article  PubMed  CAS  Google Scholar 

  • Castleton K, Fong T, Wang-Gillam A, Waqar MA, Jeffe DB, Kehlenbrink L, Gao F, Govindan R (2010) A survey of internet utilization among patients with cancer. Support Care Cancer. doi:10.1007/s00520-010-0935-5

    PubMed  Google Scholar 

  • Chabner BA (2010) New results will change the paradigm for phase 1 trials and drug approval. Oncologist 15:1023–1025

    Article  PubMed  Google Scholar 

  • Crook JM, Gomez-Iturriaga A, Wallace K, Ma C, Fung S, Alibhai S, Jewett M, Fleshner N (2011) Comparison of health-related quality of life 5 years after SPIRIT: surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol 29(4):362–368

    Article  PubMed  Google Scholar 

  • Dowlati A, Haaga J, Remick SC, Spiro TP, Gerson SL, Liu L, Berger SJ, Berger NA, Willson JK (2001) Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin Cancer Res 7(10):2971–2976

    PubMed  CAS  Google Scholar 

  • Eisenhauer EA, Twelves C, Buyse M (2006) Phase 1 Cancer Clinical Trials: A Practical Guide. Oxford University Press Inc., New York

    Google Scholar 

  • El-Osta H, Hong D, Wheeler J, Fu S, Naing A, Falchook G, Hicks M, Wen S, Tsimberidou AM, Kurzrock R (2011) Outcomes of research biopsies in phase 1 clinical trials: the MD anderson cancer center experience. Oncologist 16(9):1292–1298

    Article  PubMed  Google Scholar 

  • Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O’Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363(9):809–819

    Article  PubMed  CAS  Google Scholar 

  • Gray SW, Armstrong K, Demichele A, Schwartz JS, Hornik RC (2009) Colon cancer patient information seeking and the adoption of targeted therapy for on-label and off-label indications. Cancer 115(7):1424–1434. doi:10.1002/cncr.24186

    Article  PubMed  CAS  Google Scholar 

  • Helft PR, Daugherty CK (2006) Are we taking without giving in return? The ethics of research-related biopsies and the benefits of clinical trial participation. J Clin Oncol 24(30):4793–4795. doi:10.1200/jco.2006.05.7125

    Article  PubMed  Google Scholar 

  • Izzedine H, Isnard-Bagnis C, Launay-Vacher V, Mercadal L, Tostivint I, Rixe O, Brocheriou I, Bourry E, Karie S, Saeb S, Casimir N, Billemont B, Deray G (2006) Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant 21(11):3038–3045. doi:10.1093/ndt/gfl507

    Article  PubMed  CAS  Google Scholar 

  • Jimenez-Gordo AM, Feliu J, Martinez B, de-Castro J, Rodriguez-Salas N, Sastre N, Vilches Y, Espinosa E, Rodriguez-Aizcorbe JR, Gonzalez-Baron M (2009) Descriptive analysis of clinical factors affecting terminally ill cancer patients. Support Care Cancer 17(3):261–269. doi:10.1007/s00520-008-0460-y

    Article  PubMed  CAS  Google Scholar 

  • Kluger HM, Dudek AZ, McCann C, Ritacco J, Southard N, Jilaveanu LB, Molinaro A, Sznol M (2011) A phase 2 trial of dasatinib in advanced melanoma. Cancer 117(10):2202–2208. doi:10.1002/cncr.25766

    Article  PubMed  CAS  Google Scholar 

  • Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693–1703. doi:10.1056/NEJMoa1006448

    Article  PubMed  CAS  Google Scholar 

  • Langford A, Resnicow K, An L (2010) Clinical trial awareness among racial/ethnic minorities in HINTS 2007: sociodemographic, attitudinal, and knowledge correlates. J Health Commun 15(Suppl 3):92–101. doi:10.1080/10810730.2010.525296

    Article  PubMed  Google Scholar 

  • Maida V, Peck J, Ennis ME, Brar N, Maida AR (2010) Preferences for active and aggressive intervention among patients with advanced cancer. BMC Cancer 10:1–10

    Article  Google Scholar 

  • Mego M, De Giorgi U, Dawood S, Wang X, Valero V, Andreopoulou E, Handy B, Ueno NT, Reuben JM, Cristofanilli M (2011) Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. Int J Cancer 129(2):417–423. doi:10.1002/ijc.25690

    Article  PubMed  CAS  Google Scholar 

  • Meischke H, Bowen D, Kuniyuki A (2001) Awareness of genetic testing for breast cancer risk among women with a family history of breast cancer: effect of women’s information sources on their awareness. Cancer Detect Prev 25(4):319–327

    PubMed  CAS  Google Scholar 

  • Naing A, Stephen SK, Frenkel M, Chandhasin C, Hong DS, Lei X, Falchook G, Wheler JJ, Fu S, Kurzrock R (2011) Prevalence of complementary medicine use in a phase 1 clinical trials program. Cancer 117:5142–5150

    Article  PubMed  Google Scholar 

  • Park JW, Kerbel RS, Kelloff GJ, Barrett JC, Chabner BA, Parkinson DR, Peck J, Ruddon RW, Sigman CC, Slamon DJ (2004) Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin Cancer Res 10(11):3885–3896. doi:10.1158/1078-0432.ccr-03-0785

    Article  PubMed  CAS  Google Scholar 

  • Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3(75):75ra26. doi:10.1126/scitranslmed.3002003

    Article  PubMed  Google Scholar 

  • Shabanloei R, Golchin M, Esfahani A, Dolatkhah R, Rasoulian M (2010) Effects of music therapy on pain and anxiety in patients undergoing bone marrow biopsy and aspiration. AORN J 91(6):746–751. doi:10.1016/j.aorn.2010.04.001

    Article  PubMed  Google Scholar 

  • Sherrill B, Amonkar MM, Sherif B, Maltzman J, O’Rourke L, Johnston S (2010) Quality of life in hormone receptor-positive HER-2 + metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib. Oncologist 15(9):944–953

    Article  PubMed  CAS  Google Scholar 

  • Stewart DJ, Kurzrock R (2009) Cancer: the road to amiens. J Clin Oncol 27:328–333

    Article  PubMed  Google Scholar 

  • Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, Morris MJ, Hudes G, Calabro F, Cheng S, Trudel GC, Paliwal P, Sternberg CN (2009) Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 15(23):7421–7428. doi:10.1158/1078-0432.ccr-09-1691

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank Joann Aaron, MS, Scientific Editor, Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, for scientific editing of the manuscript.

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    David S. Hong, Goldy C. George, Eucharia C. Iwuanyanwu, Gerald S. Falchook, Sarina A. Piha-Paul, Jennifer J. Wheler, Reena H. Mistry & Razelle Kurzrock

  2. The George Washington University School of Medicine, Washington, DC, USA

    Bahareh Tavana

  3. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Xiudong Lei

Authors
  1. David S. Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Goldy C. George
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eucharia C. Iwuanyanwu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bahareh Tavana
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gerald S. Falchook
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sarina A. Piha-Paul
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jennifer J. Wheler
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Reena H. Mistry
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Xiudong Lei
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Razelle Kurzrock
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David S. Hong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hong, D.S., George, G.C., Iwuanyanwu, E.C. et al. Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy. J Cancer Res Clin Oncol 139, 963–970 (2013). https://doi.org/10.1007/s00432-013-1404-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-013-1404-6

Keywords

Search

Navigation